StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Inovio Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Inovio Pharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -130000.0%. For fiscal 2025 it was -130000.0%, against -49254.3% the year before. The highest annual figure on record is -71.9% in fiscal 2015.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-130000.0%−80745.7
FY2024Dec 31, 2024-49254.3%−33014.4
FY2023Dec 31, 2023-16239.9%−13513.2
FY2022Dec 31, 2022-2726.7%+14383.2
FY2021Dec 31, 2021-17109.9%−14864.5
FY2020Dec 31, 2020-2245.4%+657.4
FY2019Dec 31, 2019-2902.8%−2584.6
FY2018Dec 31, 2018-318.1%−109.2
FY2017Dec 31, 2017-208.9%−0.4
FY2016Dec 31, 2016-208.5%−136.6
FY2015Dec 31, 2015-71.9%+273.5
FY2014Dec 31, 2014-345.4%+144.8
FY2013Dec 31, 2013-490.3%−12.7
FY2012Dec 31, 2012-477.6%−321.8
FY2011Dec 31, 2011-155.7%+130.9
FY2010Dec 31, 2010-286.6%−19.0
FY2009Dec 31, 2009-267.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-30140.5%−21405.7
Q4 FY2024Dec 31, 2024-16566.4%−841.1
Q2 FY2024Jun 30, 2024-31993.3%+3371.5
Q4 FY2023Dec 31, 2023-24357.9%+19329.3
Q3 FY2023Sep 30, 2023-8734.8%−8322.0
Q2 FY2023Jun 30, 2023-15725.3%−1893.3
Q1 FY2023Mar 31, 2023-35364.8%+4356.0
Q4 FY2022Dec 31, 2022-43687.2%−30942.0
Q3 FY2022Sep 30, 2022-412.8%+20214.4
Q2 FY2022Jun 30, 2022-13832.0%+16275.3
Q1 FY2022Mar 31, 2022-39720.8%−25061.9
Q4 FY2021Dec 31, 2021-12745.3%−12309.2
Q3 FY2021Sep 30, 2021-20627.2%−28744.5
Q2 FY2021Jun 30, 2021-30107.3%+18062.3
Q1 FY2021Mar 31, 2021-14658.9%−12207.2
Q4 FY2020Dec 31, 2020-436.1%+13039.2
Q3 FY2020Sep 30, 20208117.3%+10781.0
Q2 FY2020Jun 30, 2020-48169.7%−26509.3
Q1 FY2020Mar 31, 2020-2451.7%−1419.2
Q4 FY2019Dec 31, 2019-13475.4%−12158.3
Q3 FY2019Sep 30, 2019-2663.7%−1413.5
Q2 FY2019Jun 30, 2019-21660.3%−21633.2
Q1 FY2019Mar 31, 2019-1032.5%+1082.4
Q4 FY2018Dec 31, 2018-1317.1%−1072.4
Q3 FY2018Sep 30, 2018-1250.2%+40.5
Q2 FY2018Jun 30, 2018-27.2%+19.3
Q1 FY2018Mar 31, 2018-2114.9%−1892.4
Q4 FY2017Dec 31, 2017-244.7%+63.4
Q3 FY2017Sep 30, 2017-1290.8%−1125.2
Q2 FY2017Jun 30, 2017-46.4%–
Q1 FY2017Mar 31, 2017-222.5%–
Q4 FY2016Dec 31, 2016-308.1%–
Q3 FY2016Sep 30, 2016-165.5%–

More Inovio Pharmaceuticals figures

See a number that looks wrong?